• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Soc Nephrol Presentation and Outcomes of Patients With ESKD and COVID-19

tetano

Editor, Senior Moderator
J Am Soc Nephrol


. 2020 May 28;ASN.2020040470.
doi: 10.1681/ASN.2020040470. Online ahead of print.
Presentation and Outcomes of Patients With ESKD and COVID-19


Anthony M Valeri[SUP] 1 [/SUP], Shelief Y Robbins-Juarez[SUP] 1 [/SUP], Jacob S Stevens[SUP] 1 2 [/SUP], Wooin Ahn[SUP] 1 [/SUP], Maya K Rao[SUP] 1 [/SUP], Jai Radhakrishnan[SUP] 1 [/SUP], Ali G Gharavi[SUP] 1 [/SUP], Sumit Mohan[SUP] 1 2 3 [/SUP], S Ali Husain[SUP] 4 2 [/SUP]



Affiliations

Abstract

Background: The relative immunosuppression and high prevalence of comorbidities in patients with ESKD on dialysis raise concerns that they may have an elevated risk of severe coronavirus disease 2019 (COVID-19), but outcomes for COVID-19 in such patients are unclear.
Methods: To examine presentation and outcomes of COVID-19 in patients with ESKD on dialysis, we retrospectively collected clinical data on 59 patients on dialysis who were hospitalized with COVID-19. We used Wilcoxon rank sum and Fischer exact tests to compare patients who died versus those still living.
Results: Two of the study's 59 patients were on peritoneal dialysis, and 57 were on hemodialysis. Median age was 63 years, with high prevalence of hypertension (98%) and diabetes (69%). Patients who died were significantly older than those still living (median age, 75 versus 62 years) and had a higher median Charlson comorbidity index (8 versus 7). The most common presenting symptoms were fever (49%) and cough (39%); initial radiographs most commonly showed multifocal or bilateral opacities (59%). By end of follow-up, 18 patients (31%) died a median 6 days after hospitalization, including 75% of patients who required mechanical ventilation. Eleven of those who died had advanced directives against intubation. The remaining 41 patients (69%) were discharged home a median 8 days after admission. The median initial white blood cell count was significantly higher in patients who died compared with those still living (7.5 versus 5.7?10[SUP]3[/SUP]/μl), as was C-reactive protein (163 versus 80 mg/L).
Conclusions: The association of COVID-19 with high mortality in patients with ESKD on dialysis reinforces the need to take appropriate infection control measures to prevent COVID-19 spread in this vulnerable population.

Keywords: COVID-19; ESRD; Epidemiology and outcomes; coronavirus; dialysis.
 
Back
Top Bottom